Host Defense Antimicrobial Peptides (HDPs) as Regulators of Hemostasis and Vascular Biology
Authors:
- Sergio Roberto Aguilar-RuizSASergio Roberto Aguilar-Ruiz
- Francisco Javier Sánchez-PeñaFSFrancisco Javier Sánchez-Peña
- Héctor Maximino Rodríguez-MagadánHRHéctor Maximino Rodríguez-Magadán
- Miguel Angel Domínguez-MartínezMDMiguel Angel Domínguez-Martínez
- Héctor Ulises Bernardino-HernándezHBHéctor Ulises Bernardino-Hernández
- Alba Soledad Aquino-DomínguezAAAlba Soledad Aquino-Domínguez
Open Access
- 2 February 2026
- journal article
- review article
- Published by MDPI AG in Biomolecules
- Vol. 16 (2) , 220
Abstract
Host defense peptides (HDPs), ancestral effectors of innate immunity, have emerged as pleiotropic regulators transcending their antimicrobial origins. This review critically examines the complex interplay among HDPs, hemostasis, and tissue repair. We analyze molecular mechanisms governing interactions with platelets and endothelial cells, highlighting a fundamental paradigm shift: platelets and megakaryocytes are active synthesizers of a specific peptide repertoire rather than passive carriers. Functional dualities are elucidated, contrasting LL-37-driven platelet agonism via glycoprotein VI (GPVI) against the amyloid-like stabilization of fibrin by defensins. Based on these mechanisms, we propose a framework wherein HDPs function as concentration-dependent molecular switches between physiological repair and pathological thromboinflammation. Furthermore, the review addresses the hypothesis of “adaptive thrombopoiesis,” where systemic peptide surges act as danger signals to reprogram the function of newly formed platelets. Finally, therapeutic implications are evaluated, emphasizing the design of protease-resistant peptidomimetics to harness protective effects while mitigating vascular toxicity.Keywords
This publication has 101 references indexed in Scilit:
- Advances in antimicrobial peptides: From mechanistic insights to chemical modificationsBiotechnology Advances, 2025
- Antimicrobial peptides: An alternative strategy to combat antimicrobial resistanceDrug Discovery Today, 2025
- Peceleganan Spray for the Treatment of Skin Wound InfectionsJAMA Network Open, 2024
- The synergy of LL-37 with human defensins protects POPC bilayers from lysisBiophysical Journal, 2024
- Between good and evil: Complexation of the human cathelicidin LL-37 with nucleic acidsBiophysical Journal, 2023
- Brilacidin, a COVID‐19 drug candidate, demonstrates broad‐spectrum antiviral activity against human coronaviruses OC43, 229E, and NL63 through targeting both the virus and the host cellJournal of Medical Virology, 2022
- Fabricating antimicrobial peptide-immobilized starch sponges for hemorrhage control and antibacterial treatmentCarbohydrate Polymers, 2019
- Arginine-lysine positional swap of the LL-37 peptides reveals evolutional advantages of the native sequence and leads to bacterial probesBiochimica et Biophysica Acta (BBA) - Biomembranes, 2017
- The human cathelicidin LL-37 — A pore-forming antibacterial peptide and host-cell modulatorBiochimica et Biophysica Acta (BBA) - Biomembranes, 2016
- Human platelets exhibit chemotaxis using functional N-formyl peptide receptorsExperimental Hematology, 2005